Critical phase III FORTRESS trial balixafortide in mBC remains on track to report results in 2021.
Up to CHF 24 mn grants awarded from CARB-X and CFF to support development of new antibiotic programs and inhaled murepavadin.
New CXCR4 lead compound announced and new “wild card” COVID-19 indication for balixafortide.
Balixafortide pivotal phase III “FORTRESS” ORR results (Q2 2021)
New CXCR4 lead candidate (Q2 2021)
Balixafortide pivotal phase III “FORTRESS” PFS results (Q4 2021)